HC Wainwright & Co. Maintains Buy on Regenxbio, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Regenxbio (NASDAQ:RGNX) and raised the price target from $38 to $39.
August 05, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Regenxbio and raised the price target from $38 to $39, indicating confidence in the company's future performance.
The maintained Buy rating and increased price target from a reputable analyst firm suggest positive sentiment and potential for stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100